Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents

Natalie Boytsov, Molly Purser, Richard Zur, Yevgeniy Samyshkin, Teresa Palumbo, Torey Batts, Michelle Kamdar, James Osborne, Cheryl Ferrufino

Blood (2025) 146 (Supplement 1): 7922.

https://doi.org/10.1182/blood-2025-7922

Published: 2025

Journal Articles

Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy

Attaya Suvannasankha, Benga Kazeem, Paul MacLeod, Ewa Dlotko, Natalie Boytsov, Yevgeniy Samyshkin, Simon McNamara, Molly Purser, Sandhya Sapra, Martin Kaiser

Blood (2025) 146 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2025-4041

Published: 2025

Journal Articles

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

Sagar Lonial, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Jacqueline Nielsen, Benga Kazeem, Farrah Pompilus, Paul Richardson

Blood (2025) 146 (Supplement 1): 4029.

https://doi.org/10.1182/blood-2025-4029

Published: 2025

Journal Articles

Bispecific antibodies in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization

Natalie Boytsov, Jasjit Multani, Molly Purser, Zifan Zhou, Nicole Niehoff, John Hartman, Teresa Palumbo, Chi-Chang Chen

Blood (2025) 146 (Supplement 1): 2790.

https://doi.org/10.1182/blood-2025-2790

Published: 2025

Journal Articles

Chimeric antigen receptor T cells in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization

Natalie Boytsov, Jasjit Multani, Molly Purser, Zifan Zhou, Nicole Niehoff, John Hartman, Teresa Palumbo, Chi-Chang Chen

Blood (2025) 146 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2025-2787

Published: 2025

Journal Articles

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

Joshua Richter, Meral Beksac, Alessandro Corso, Ollie Schofield, Dani Olivier, Leanne Cooper, Owen Harrison, Jacopo Bitetti, Benga Kazeem, Alex Bates, Natalie Boytsov, Simon McNamara, Adil Merchant, Connor Lloyd, Christina-Jane Crossman-Morgan, Nicholas Meader, Molly Purser, Nick Ballew

Blood (2025) 146 (Supplement 1): 7567.

https://doi.org/10.1182/blood-2025-7567

Published: 2025

Journal Articles

An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8

Paul Richardson, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Benga Kazeem, Farrah Pompilus, Sagar Lonial

Blood (2025) 146 (Supplement 1): 2284.

https://doi.org/10.1182/blood-2025-2284

Published: 2025

Journal Articles

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Suzanne Trudel, Vania Hungria, María-Victoria Mateos, Chee Paul Lin, Julie Byrne, James Parker, Molly Purser, Sandhya Sapra, Farrah Pompilus, Sumita Roy-Ghanta, Giulia Fulci, Joanna Opalinska, Neal Sule, Brandon Kremer, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2025-5823

Published: 2025

Journal Articles

The Impact of Patient-Reported Adverse Events on Quality of Life: An Analysis of the Dreamm-7 and Dreamm-8 Randomized Controlled Trials

Angely Loubert, Laurine Bunod, Manal M'Hari, Farrah Pompilus, Molly Purser, Simon McNamara

Blood (2024) 144 (Supplement 1): 3358.

https://doi.org/10.1182/blood-2024-200299

Published: 2024

Journal Articles

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Paula Rodríguez-Otero, Joshua Richter, Ajay K. Nooka, Fredrik Schjesvold, Emily Combe, Leanne Cooper, Ollie Schofield, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Simon McNamara, Molly Purser

Blood (2024) 144 (Supplement 1): 7054.

https://doi.org/10.1182/blood-2024-198712

Published: 2024

Journal Articles

The Relationship between Anemia, Transfusion Dependence, Quality of Life and Survival in Myelofibrosis

Aaron T. Gerds, Fulya Sen Nikitas, Shiyuan Zhang, Molly Purser, Seán Conlon, Anuja Pandey, Ike Iheanacho, Balazs Dobi, Venediktos Kapetanakis

Blood (2024) 144 (Supplement 1): 6677.

https://doi.org/10.1182/blood-2024-207828

Published: 2024

Journal Articles

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Vikas Gupta, Claire N Harrison, Boris Gorsh, Bharat Patel, Zhaohui Wang, Molly Purser, Catherine Ellis, Bryan Strouse, Dwaipayan Patnaik, Jun Kawashima, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 3188.

https://doi.org/10.1182/blood-2023-178772

Published: 2023

Journal Articles

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik

Blood (2023) 142 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2023-177784

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents

Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

Bispecific antibodies in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization

Chimeric antigen receptor T cells in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

The Impact of Patient-Reported Adverse Events on Quality of Life: An Analysis of the Dreamm-7 and Dreamm-8 Randomized Controlled Trials

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

The Relationship between Anemia, Transfusion Dependence, Quality of Life and Survival in Myelofibrosis

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only